H. Lundbeck A/S announced results from FOCUS, a new study showing that Brintellix (vortioxetine) 10 mg and 20 mg, met...
Watch our short and informative videos featuring experts Professor Robert Storey and Dr Marc P Bonaca.
Mateon Therapeutics, Inc. announced results from its third scheduled interim analysis of the phase II/III FOCUS study evaluating CA4P (fosbretabulin)in...
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc. announced that the Phase III clinical trial FOCUS (CarFilzOmib for AdvanCed Refractory MUltiple...
Advaxis, Inc. announced that it is increasing its focus on neoantigen-directed immunotherapies and closing the AIM2CERV Phase III clinical trial...
Synta Pharmaceuticals Corp. and Madrigal Pharmaceuticals,Inc., a privately-held company announced that they have entered into a definitive merger agreement under which...
Focus Diagnostics has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 &...
Focus Diagnostics announced that its Simplexa Flu A/B & RSV Direct Kit has received 510(k) clearance from the FDA for...
Coverage of the latest on metastaic castration resitant prostate cancer (mCRPC) from ASCO Genitourinary Cancers Symposium 2024 including BRCAAway, the ACE study and CONTACT-02.
Focus Diagnostics has announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit....